Amino-PEG4-(CH2)3CO2H - CAS 144598-03-8

The first aromatic quaternary ammonium-group-containing [FeFe]H2ase models have been prepared by a simple and convenient two-step method in high yields. Thus, on the basis of preparation of the N-pyridylazadiphosphine-bridged diiron complex (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NC5H4N] (A) by CO substitution of parent complex (μ-PDT)Fe2(CO)6 with N-pyridylazadiphosphine 3-(Ph2P)2NC5H4N in refluxing xylene, further quaternization of the pyridyl N atom in complex A with electrophile 1,3-propanesultone, 1,3,2-dioxathiolane-2,2-dioxide, or 4-bromobutyric acid in refluxing MeCN afforded the pyridyl quaternary ammonium-group-containing models (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NC5H4NR] (1, R = (CH2)3SO3; 2, R = (CH2)2OSO3) and (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NC5H4N(CH2)3CO2H]Br (3). Similarly, the N-pyridylmethylazadiphosphine-bridged diiron complex (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NCH2C5H4N] (B) could be prepared by CO substitution of parent complex (μ-PDT)Fe2(CO)6 with N-pyridylmethylazadiphosphine 3-(Ph2P)2NCH2C5H4N in refluxing xylene, while further quaternization of the pyridylmethyl N atom in complex B with 1,3-propanesultone and 3-bromo-1-propanol in MeCN at reflux resulted in formation of the pyridylmethyl quaternary ammonium-group-containing models (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NCH2C5H4N(CH2)3SO3] (4) and (μ-PDT)Fe2(CO)4[μ-3-(Ph2P)2NCH2C5H4N(CH2)3OH]Br (5), respectively. All new complexes A, B, and 1-5 were characterized by elemental analysis and various spectroscopies, while the molecular structures of complexes A, B, 2 and 5 were further confirmed by X-ray crystallography. The electrochemical study on hydrophilic models 1 and 3 in MeCN and the MeCN/H2O mixed solvent indicated that the reduction potentials were shifted to less-negative potentials as the water content increased; such an observation implies that both 1 and 3 are easily reduced in the mixed MeCN/H2O solvent than in MeCN. In addition, the electrocatalytic study demonstrated that both 1 and 3 can serve as electrocatalysts for H2 production from acetic acid with higher icat/ip and TONs in MeCN/H2O than in MeCN.

Here we report the coordination behaviour of an imidazole-based [S1]-donor ligand, 1,3-dimethyl-imidazole-2(3H)-thione (L1), and [S2]-donor ligand, 3,3'-methylenebis(1-methyl-imidazole-2(3H)-thione) (L2) or 4,4'-(3,3'-methylenebis-(2-thioxo-2,3-dihydro-imidazole-3,1-diyl))dibutanoic acid (L3), with HgX2 (X = Cl, Br or I) in solution and the solid state. NMR, UV-Vis spectroscopic, and single crystal X-ray studies demonstrated that L1 or L2 coordinated rapidly and reversibly to the mercury center of HgX2 through the thione moiety. Treatment of L2 with HgCl2 or HgBr2 afforded 16-membered metallacycle k1-(L2)2Hg2Cl4 or k1-(L2)2Hg2Br4 where two Cl or Br atoms are located inside the ring. In contrast, treatment of L2 with HgI2 afforded a chain-like structure of k1-[L2Hgl2]n, possibly due to the large size of the iodine atom. Interestingly, [S1] and [S2]-donor ligands (L1, L2, and L3) showed an excellent efficacy to protect liver cells against HgCl2 induced toxicity and the strength of their efficacy is in the order of L3 > L2 > L1. 30% decrease of ROS production was observed when liver cells were co-treated with HgCl2 and L1 in comparison to those cells treated with HgCl2 only. In contrast, 45% and 60% decrease of ROS production was observed in the case of cells co-treated with HgCl2 and thiones L2 and L3, respectively, indicating that [S2]-donor ligands L2 and L3 have better cytoprotective effects against oxidative stress induced by HgCl2 than [S1]-donor ligand L1. Water-soluble ligand L3 with N-(CH2)3CO2H substituents showed a better cytoprotective effect against HgCl2 toxicity than L2 in liver cells.

High radiolabeling efficiency, preferably to high specific activity, and good stability of the radioimmunoconjugate are essential features for a successful immunoconjugate for imaging or therapy. In this study, the radiolabeling efficiency, in vitro stability, and biodistribution of immunoconjugates with eight different bifunctional chelators labeled with (64)Cu were compared. The anti-CD20 antibody, rituximab, was conjugated to four macrocyclic bifunctional chelators (p-SCN-Bn-DOTA, p-SCN-Bn-Oxo-DO3A, p-SCN-NOTA, and p-SCN-PCTA), three DTPA derivatives (p-SCN-Bn-DTPA, p-SCN-CHX-A″-DTPA, and ITC-2B3M-DTPA), and a macrobicyclic hexamine (sarcophagine) chelator (sar-CO2H) = (1-NH2-8-NHCO(CH2)3CO2H)sar where sar = sarcophagine = 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane). Radiolabeling efficiency under various conditions, in vitro stability in serum at 37 °C, and in vivo biodistribution and imaging in normal mice over 48 h were studied. All chelators except sar-CO2H were conjugated to rituximab by thiourea bond formation with an average of 4.9 ± 0.9 chelators per antibody molecule. Sar-CO2H was conjugated to rituximab by amide bond formation with 0.5 chelators per antibody molecule. Efficiencies of (64)Cu radiolabeling were dependent on the concentration of immunoconjugate. Notably, the (64)Cu-NOTA-rituximab conjugate demonstrated the highest radiochemical yield (95%) under very dilute conditions (31 nM NOTA-rituximab conjugate). Similarly, sar-CO-rituximab, containing 1/10th the number of chelators per antibody compared to that of other conjugates, retained high labeling efficiency (98%) at an antibody concentration of 250 nM. In contrast to the radioimmunoconjugates containing DTPA derivatives, which demonstrated poor serum stability, all macrocyclic radioimmunoconjugates were very stable in serum with <6% dissociation of (64)Cu over 48 h. In vivo biodistribution profiles in normal female Balb/C mice were similar for all the macrocyclic radioimmunoconjugates with most of the activity remaining in the blood pool up to 48 h. While all the macrocyclic bifunctional chelators are suitable for molecular imaging using (64)Cu-labeled antibody conjugates, NOTA and sar-CO2H show significant advantages over the others in that they can be radiolabeled rapidly at room temperature, under dilute conditions, resulting in high specific activity.